Vildagliptin modulates the microbiota and induces an immunometabolic profile …

Dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4i) are widely used to treat Type 2 diabetes (T2D) and are known for their cardiovascular and renal safety profiles. Systematic reviews have also shown that DPP-4i are associated with reduced dementia risk via unknown mechanisms. To examine vildagliptin (DPP-4i) effects on the intestinal microbiota in T2D patients, plasma metabolomics were conducte…

Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined…

The aim of this paper is to evaluate the efficacy and safety of DLBS3233, a novel bioactive fraction derived from Cinnamomum burmanii and Lagerstroemia speciosa, in improving insulin resistance and preserving β-cell performance in patients with impaired glucose tolerance (IGT).

Dapagliflozin: A Review in Type 2 Diabetes

Dapagliflozin ( Forxiga®) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for …

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diab…

Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week trials in treatment-naı¨ve patients to compare dapagliflozin plus metformin, dapagliflozin alone and metformin alone.

Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitra…

To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy.

Glimepiride : A Review of its Use in the Management of Type 2 Diabetes Mellitus

Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic b-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non–insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and exercise alone, and may be combined with insulin in patients with secondary sulphonylurea failure

The pathophysiologic basis of efficacy and clinical experience with the new o…

Type 2 diabetes results from the abnormal resistance of peripheral tissues to insulin and from the progressive insulin secretory failure of the pancreatic b-cells. Treatment of type 2 diabetes has greatly improved due to the availability of new classes of oral antidiabetic drugs (OADs) and new insulin analogs. Three types of oral medications exert their antidiabetic action without directly stim…

Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors …

To assess the efficacy and safety of Dipeptidyl Peptidase IV (DPP-4) inhibitors in patients with Type-2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) using level 1 evidence.

Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systema…

Gliclazide has been associated with a low risk of hypoglycemic episodes and beneficial long-term cardiovascular safety in observational cohorts. The aim of this study was to assess in a systematic review and meta-analysis of randomized controlled trials the safety and efficacy of gliclazide compared to other oral glucose-lowering agents (PROSPERO2013:CRD42013004156)

Panduan Lengkap Pola Makan untuk Penderita Diabetes

Edition

-

ISBN/ISSN

978-979-22-6348-0

Collation

-

Series Title

-

Call Number

616.462 TJO p